BI Focuses COVID-19 Clinical Research on Alteplase

Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase  Analysis of first part of the TRISTARDS study (Phase 2b) investigating alteplase in patients with COVID-19 acute respiratory distress syndrome (ARDS) supports further developmentPhase 3 part of TRISTARDS to be initiated in Q4 2021SARS-CoV-2 neutralizing antibody development discontinued in light of evolving landscape including vaccination success and emerging variants
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news